Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03551288 · ClinicalTrials.gov registry record · Phase 1
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
A Phase 1 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03551288 is a Phase 1 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 28 participants.
The verdict
NCT03551288, a Phase 1 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
Interventions
- DRUG SUVN-911
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2018-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03551288
The ClinicalTrials.gov registry entry for NCT03551288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SUVN-911 is the first listed.
NCT03551288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03551288 about?
NCT03551288 is a clinical study titled "Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects". The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
What is the current status of trial NCT03551288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-05-22. Estimated completion is 2018-07-16.
What interventions are being tested in trial NCT03551288?
The interventions under investigation include: SUVN-911 (DRUG).
Who is sponsoring clinical trial NCT03551288?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.